Get started
Author

Lillian K. Skidmore

Observed names: L. Skidmore, Lillian Skidmore
Observed institution: Ambrx (United States)
ORCID: 0009-0005-8277-8223
Observed ORCID: 0009-0005-8277-8223
OpenAlex ID: A5034466570
ARX788, a Site-specific Anti-HER2 Antibody–Drug Conjugate, Demonstrates Potent and Selective Activity in HER2-low and T-DM1–resistant Breast and Gastric Cancers
2020 · Lillian Skidmore, Sukumar Sakamuri, et al. · Molecular Cancer Therapeutics · 170
FGF21 Analogs of Sustained Action Enabled by Orthogonal Biosynthesis Demonstrate Enhanced Antidiabetic Pharmacology in Rodents
2011 · James Mu, Jason Pinkstaff, et al. · Diabetes · 162
PDF
Abstract 639: Site specific conjugation of ARX-788, an antibody drug conjugate (ADC) targeting HER2, generates a potent and stable targeted therapeutic for multiple cancers
2015 · Robin C. Humphreys, Jessica Kirtely, et al. · Cancer Research · 31
Nonclinical Development of Next-generation Site-specific HER2-targeting Antibody–drug Conjugate (ARX788) for Breast Cancer Treatment
2020 · Prathap Nagaraja Shastri, Jingjing Zhu, et al. · Molecular Cancer Therapeutics · 28
Preclinical Characterization of ARX517, a Site-Specific Stable PSMA-Targeted Antibody–Drug Conjugate for the Treatment of Metastatic Castration-Resistant Prostate Cancer
2024 · Lillian K. Skidmore, David Mills, et al. · Molecular Cancer Therapeutics · 23
PDF
Analytical comparability to evaluate impact of manufacturing changes of ARX788, an Anti-HER2 ADC in late-stage clinical development
2023 · Wayne Yu, Mysore Ramprasad, et al. · PLoS ONE · 11
PDF
Prophylactic treatment with PEGylated bovine IFNλ3 effectively bridges the gap in vaccine-induced immunity against FMD in cattle
2024 · Sarah E. Attreed, Christina Silva, et al. · Frontiers in Microbiology · 5
Abstract 3997: Preclinical characterization of ARX517, a next-generation anti-PSMA antibody drug conjugate for the treatment of metastatic castration-resistant prostate cancer
2023 · Lillian Skidmore, David Mills, et al. · Cancer Research · 5
1828P ARX517: A next generation anti-PSMA antibody drug conjugate (ADC) demonstrates notable stability and pharmacokinetic (PK) profile in the ARX517 phase I clinical trial (APEX-01)
2023 · S.T. Tagawa, J. Shen, et al. · Annals of Oncology · 4
PDF
Abstract 5616: Tumor-targeted immune activation via a site-specific TLR7-agonist antibody-drug conjugate
2022 · Mingchao Kang, Sung-Ju Moon, et al. · Cancer Research · 4
41P Evaluation of ARX517: A next-generation anti-PSMA antibody drug conjugate for prostate cancer treatment, in preclinical enzalutamide-resistant and enzalutamide-sensitive pharmacology models and in toxicology models
2023 · S. Zhang, D. Mills, et al. · Annals of Oncology · 3
PDF
Abstract 6352: Preclinical discovery of ARX622: A site-specific, TLR7 agonist, HER2-targeted immune-stimulatory antibody drug conjugate for treatment of multiple solid tumor types
2024 · David Mills, Ji Young Kim, et al. · Cancer Research · 1
Porcine interferon-alpha but not interferon-lambda inhibits replication of genotypically diverse PRRSV isolates in vitro
2026 · Samantha J. Hau, Steven G. Kellner, et al. · Frontiers in Veterinary Science
PDF
Data from Preclinical Characterization of ARX517, a Site-Specific Stable PSMA-Targeted Antibody–Drug Conjugate for the Treatment of Metastatic Castration-Resistant Prostate Cancer
2024 · Lillian K. Skidmore, David Mills, et al.
Table S1 from Preclinical Characterization of ARX517, a Site-Specific Stable PSMA-Targeted Antibody–Drug Conjugate for the Treatment of Metastatic Castration-Resistant Prostate Cancer
2024 · Lillian K. Skidmore, David Mills, et al.
71P Preclinical characterization of ARX305: A next-generation anti-CD70 antibody drug conjugate for the treatment of CD70-expressing cancers
2023 · L. Skidmore, D. Mills, et al. · Annals of Oncology
PDF
Abstract 6318: Preclinical characterization of ARX305, a next-generation anti-CD70 antibody drug conjugate for the treatment of CD70-expressing cancers
2023 · Lillian Skidmore, Jingjing Zhu, et al. · Cancer Research
Supplementary Data Figure S1 from ARX788, a Site-specific Anti-HER2 Antibody–Drug Conjugate, Demonstrates Potent and Selective Activity in HER2-low and T-DM1–resistant Breast and Gastric Cancers
2023 · Lillian Skidmore, Sukumar Sakamuri, et al.
PDF
Supplementary Data Figure S2 from ARX788, a Site-specific Anti-HER2 Antibody–Drug Conjugate, Demonstrates Potent and Selective Activity in HER2-low and T-DM1–resistant Breast and Gastric Cancers
2023 · Lillian Skidmore, Sukumar Sakamuri, et al.
Supplementary Data Figure S3 from ARX788, a Site-specific Anti-HER2 Antibody–Drug Conjugate, Demonstrates Potent and Selective Activity in HER2-low and T-DM1–resistant Breast and Gastric Cancers
2023 · Lillian Skidmore, Sukumar Sakamuri, et al.
Data from ARX788, a Site-specific Anti-HER2 Antibody–Drug Conjugate, Demonstrates Potent and Selective Activity in HER2-low and T-DM1–resistant Breast and Gastric Cancers
2023 · Lillian Skidmore, Sukumar Sakamuri, et al.
Supplementary Figure S1 from Nonclinical Development of Next-generation Site-specific HER2-targeting Antibody–drug Conjugate (ARX788) for Breast Cancer Treatment
2023 · Prathap Nagaraja Shastri, Jingjing Zhu, et al.
Supplementary Method M1 from Nonclinical Development of Next-generation Site-specific HER2-targeting Antibody–drug Conjugate (ARX788) for Breast Cancer Treatment
2023 · Prathap Nagaraja Shastri, Jingjing Zhu, et al.
Supplementary Table 1 from Nonclinical Development of Next-generation Site-specific HER2-targeting Antibody–drug Conjugate (ARX788) for Breast Cancer Treatment
2023 · Prathap Nagaraja Shastri, Jingjing Zhu, et al.
Supplementary Methods M2 from Nonclinical Development of Next-generation Site-specific HER2-targeting Antibody–drug Conjugate (ARX788) for Breast Cancer Treatment
2023 · Prathap Nagaraja Shastri, Jingjing Zhu, et al.
Works count: 34
Citation count: 447
H-index: 6
I10-index: 6
Year
Topic
Type